Journal of Clinical Oncology
Articles in this Issue
Adjuvant vs switch-maintenance checkpoint inhibition in urothelial carcinoma: A systematic review and meta-analysis of randomized trials through July 2025.
732 Background: Immune checkpoint inhibitors (ICIs) are used in urothelial carcinoma (UC) as adjuvant therapy after radica...
Single-cell transcriptomic investigation of the cell-of-origin and oncogenic pathways across variant histologies of renal cell carcinoma.
552 Background: RCC has multiple distinct molecular and histological subtypes. Prior studies suggest that clear cell RCC (...
Effect of maximal transurethral resection before neoadjuvant chemotherapy on pathological response and survival in patients undergoing radical cystectomy for muscle-invasive bladder cancer: A multicenter retrospective study.
777 Background: Bladder-preserving trimodal therapy, which combines maximal transurethral resection (TUR) and concurrent c...
Predictive role of peripheral blood erythroblasts for treatment intensification in metastatic hormone-sensitive prostate cancer.
65 Background: Androgen deprivation therapy (ADT) combined with an androgen receptor pathway inhibitor (ARPI) represents t...
Demographic predictors of primary retroperitoneal lymph node dissection (P-RPLND) vs. primary chemotherapy (P-Ch) in the treatment of clinical stage IIA/B (CSIIA/B) non-seminomatous testicular germ cell tumors (NSGCTs).
594 Background: Traditional treatment for CSIIA/B NSGCTs has been primary cisplatin-based chemotherapy (P-Ch) or primary R...
miR-371a-3p as a potential biomarker for monitoring disease activity and therapeutic response in metastatic seminoma and non-seminomatous germ cell tumor patients treated with BEP chemotherapy.
616 Background: MicroRNA 371 (miR-371a-3p) is a promising biomarker for germ cell tumors. Its expression in blood may prov...
RNA based liquid biopsy testing of urine to predict pathological complete response to radiomolecular instillation NAC therapy before surgery: The Bladder BRIDGister experience.
643 Background: Patients with MIBC achieving pathological complete response (pCR) upon neoadjuvant chemotherapy (NACT) hav...
Real-world comparative effectiveness of novel doublet therapies for metastatic hormone-sensitive prostate cancer.
70 Background: Metastatic hormone-sensitive prostate cancer (mHSPC) is an advanced form of prostate cancer with a 5-year s...
Fruquintinib combined with everolimus in Chinese patients with advanced/metastatic clear cell renal cell carcinoma (ccRCC) after progression on immune checkpoint inhibitors (ICIs): Results from a phase II single arm clinical trial.
497 Background: Patients with clear cell renal cell carcinoma (ccRCC) progressing after immune checkpoint inhibitors (ICIs...
Integrative genomic landscape of germline exome alterations in renal cell carcinoma, unclassified with medullary phenotype.
524 Background: SMARCB1-deficient Renal Medullary Carcinoma (RMC) is a rare non-clear cell renal cell carcinoma predominan...
The GAIN trial: Gemcitabine alternating with intravesical BCG randomized against BCG alone for patients with recurrent “BCG-exposed” high-grade non-muscle invasive bladder cancer (NMIBC) (ALLIANCE A032303).
TPS909 Background: BCG-Exposed NMIBC (a high grade recurrence within 24 months of prior BCG, but not meeting “unresponsive...
Phase 2 expansion study of <sup>212</sup> Pb-ADVC001 in metastatic prostate cancer: The TheraPb trial.
TPS280 Background: 212 Pb-ADVC001 (ADVC001) is an alpha-emitting PSMA-targeting radioligand therapy (R...
Biopsy patterns following high intensity focused ultrasound as assessed by CAPRA score.
324 Background: Cancer of the Prostate Risk Assessment (CAPRA) score determines the overall risk of recurrence after patie...
Structured step-based prehabilitation before radical cystectomy and its impact on postoperative recovery and perioperative burden: Interim analysis of the PRACTICE randomized trial (NCT06806059).
662 Background: Radical cystectomy (RC) is associated with substantial morbidity, functional decline, and impaired quality...
Inclusion of patients from Latin America in pivotal trials in genitourinary (GU) and cutaneous malignancies.
646 Background: Latin America bears an increasing burden of both genitourinary (GU) and cutaneous malignancies but remains...
A phase I clinical trial of autologous gamma delta T cells genetically engineered with a chimeric receptor to target the prostate stem cell antigen in patients with metastatic castration-resistant prostate cancer.
TPS287 Background: Prostate Stem Cell Antigen (PSCA) is a glycosylphosphatidyl inositol-anchored cell surface protein that...
Clinical outcomes in the real-world utilization of 177Lu-PSMA 617 in metastatic castrate-resistant prostate cancer.
104 Background: 177Lu-PSMA-617 (177Lu) is an established therapy for PSMA-PET–positive metastatic castration-resistant pro...
Geographic disparities in the availability of renal cell carcinoma (RCC) clinical trials in the United States (US).
431 Background: Clinical trials for cancer tend to be less available in regions of the US corresponding to high socioecono...
Real-world characteristics of long-term survivors with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): An analysis of the global REASSURE study.
74 Background: Ra-223 is an alpha-emitting radionuclide approved to treat mCRPC with bone metastases. The REASSURE study (...
Germline radiosensitivity biomarker for radiation-induced GU toxicity following radiation therapy in localized prostate cancer (GARUDA): Two-year outcomes of a phase II clinical trial.
359 Background: Stereotactic body radiation therapy (SBRT) is increasingly used for localized prostate cancer, yet treatme...
Discontinuation rates among patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating novel androgen receptor inhibitors in oncology and non-oncology settings.
105 Background: Novel androgen receptor pathway inhibitors (ARPI) apalutamide (Apa), darolutamide (Daro), and enzalutamide...
Development and validation of computational histology artificial intelligence (CHAI)–powered prognostic and predictive biomarkers in metastatic hormone-sensitive prostate cancer (mHSPC) using ENZAMET and CHAARTED prospective randomized phase 3 trials (RCT).
231 Background: Advanced biomarkers (BM) for mHSPC are needed to improve personalized treatment. The CHAI platform applies...
Precision diagnostics in prostate cancer treatment (PREDICT): A phase 2 multi-arm biomarker-based study (Alliance A032102).
TPS277 Background: Recent advances in genomic sequencing have deepened our understanding of the molecular complexity of me...
Detecting <i>FGFR3</i> genomicalterations in liquid biopsies from patients with clinically advanced urothelial bladder cancer.
830 Background: Fibroblast growth factor receptor 3 (FGFR3) pathogenic gain of fun...
Can clinico-genomic characterization reveal more aggressive prostate cancer among older patients with lower Gleason grade groups?
395 Background: The prevalence of prostate cancer (PCa) increases with age, with the average age of diagnosis being 66. Cu...